Pu Kuang

ORCID: 0000-0002-1007-6784
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Childhood Cancer Survivors' Quality of Life
  • Renal Transplantation Outcomes and Treatments
  • Eosinophilic Disorders and Syndromes
  • CNS Lymphoma Diagnosis and Treatment
  • Mesenchymal stem cell research
  • Immune Cell Function and Interaction
  • Adrenal and Paraganglionic Tumors
  • Neuroblastoma Research and Treatments
  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Pathogenesis and Treatment of Hiccups
  • Nausea and vomiting management
  • Viral-associated cancers and disorders
  • Biosensors and Analytical Detection
  • Neutropenia and Cancer Infections
  • Neurological Complications and Syndromes
  • Myasthenia Gravis and Thymoma
  • Protein Degradation and Inhibitors
  • Colorectal and Anal Carcinomas

Sichuan University
2015-2024

West China Hospital of Sichuan University
2014-2024

Tibet Autonomous Region People's Hospital
2022

Interpreting an electrocardiogram (ECG) is not only one of the most important parts diagnostics but also difficult areas to teach. Owing abstract nature basic theoretical knowledge ECG, its scattered characteristics, and tedious difficult-to-remember subject matter, teaching how interpret ECGs as for teachers teach it students learn. In order enable medical master ECG interpretation skills in a limited time, we modified content used traditional now propose new method called...

10.2147/amep.s75316 article EN cc-by-nc Advances in Medical Education and Practice 2015-02-01

Previous studies highlight the need for a more active conditioning therapy in high-risk or refractory and relapsed lymphomas. Our preclinical research shows that histone deacetylase inhibitors, such as either vorinostat chidamide, sensitize lymphoma cells to cytotoxic combination of cladribine, gemcitabine busulfan, leading cell apoptosis. To evaluate efficacy this chidamide-cladribine-gemcitabine-busulfan (ChiCGB) new therapy, we conducted Phase II trial, described here. Patients with...

10.1002/ijc.33761 article EN International Journal of Cancer 2021-08-16

Cancer is a malignant disease that seriously affects human health and life. Early diagnosis timely treatment can significantly improve the survival rate of cancer patients. Surface-enhanced Raman scattering (SERS) an optical technology detect image samples at single-molecule level. It has advantages rapidity, high specificity, sensitivity no damage to sample. The performance SERS highly dependent on properties, size morphology substrate. Preparation substrates with good reproducibility...

10.2217/nnm-2021-0298 article EN Nanomedicine 2021-09-17

Background: The development of tyrosine kinase inhibitor (TKI) therapy has positively impacted the survival rates patients with chronic myeloid leukemia (CML). It is common in medical practice to adjust dosage TKI downward because TKI-associated adverse events, financial burden, comorbidity, or an attempt at treatment-free remission. Objectives: This investigation sought explore feasibility employing a reduced for treating CML. Design: was retrospective study. Methods: Patients CML its phase...

10.1177/20406207241259678 article EN cc-by-nc Therapeutic Advances in Hematology 2024-01-01

We retrospectively analyzed the samples collected from 66 patients with Ph+ALL enrolled on ChiCTR-TNRC-09000309 clinical trial. CR rate was 95.5%, and estimated 2-year OS DFS were 51.7 ± 11.7% 26.9 11.6%, 3-year 31.6 12.0% 23.4 11.6%. By combining IKZF1 deletion early molecular responses, we redefined as low, intermediate, high risk 3 groups separately. Patients double negative in response experienced significant superior survival, while positive would have worst outcome, who one or other...

10.1080/10428194.2017.1406933 article EN Leukemia & lymphoma/Leukemia and lymphoma 2017-12-07

We report the clinical results of sustainedly integrating imatinib and interferon-α into maintenance therapy in patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Maintenance lasted 5 years with 400 mg daily, 3 million units, 2∼3 doses per week, chemotherapy including vindesine dexamethasone scheduled monthly first year, once every 2 months second third year. The was discontinued after continued another years. For 41 without allo-HSCT a median follow-up...

10.3109/10428194.2016.1144882 article EN Leukemia & lymphoma/Leukemia and lymphoma 2016-02-16

Acute lymphoblastic leukemia (ALL) has a rapid onset and rarely occurs with exclusive prodrome of general osteoporosis vertebral compression fractures. However, Philadelphia chromosome-positive (Ph+) ALL poor prognosis, even when patients are treated intensive chemotherapy, the first-line effective treatment requires further elucidation. The present study focused on 56-year-old Chinese male patient who initially presented spontaneous bone fractures was ultimately diagnosed as Ph+ after 6...

10.3892/ol.2015.3539 article EN Oncology Letters 2015-07-28

The prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic lymphoma (T-LBL) remains poor under current conditioning regimens before receiving autologous stem cell transplantation (ASCT).Patients PTCL T-LBL were enrolled to receive ASCT using the regimen chidamide, cladribine, gemcitabine, and busulfan (ChiCGB). Positron emission tomography-computed tomography (PET/CT) was used evaluate response ASCT. Overall survival (OS) progression-free (PFS) employed assess patient outcome,...

10.3389/fonc.2023.1143556 article EN cc-by Frontiers in Oncology 2023-03-09

Acute graft versus host disease (aGvHD) is a severe complication that arises in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remains the primary cause of nonrelapse mortality (NRM). The MAGIC algorithm probability (MAP) has been proposed to identify at intermediate high risk developing aGvHD. levels suppression tumorigenicity 2 (ST2) regenerating islet-derived 3α (Reg3α) were assessed, MAP was calculated on days 7, 14, 21, 28 after allo-HSCT. Based...

10.1002/ajh.27020 article EN American Journal of Hematology 2023-07-27

To the Editor: As of July 4, 2021, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has affected >0.18 billion individuals and caused >3.9 million deaths worldwide.[1] Currently, only method to radically overcome this is extensive vaccination. However, clinical trials assessing most vaccines against SARS-CoV-2 have excluded patients with hematological tumors. Thus, limited data are available in tumor respect vaccine safety, tolerability, effectiveness. The lack such...

10.1097/cm9.0000000000001899 article EN cc-by-nc-nd Chinese Medical Journal 2021-12-30
Coming Soon ...